![A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies | SpringerLink A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12325-016-0451-1/MediaObjects/12325_2016_451_Fig2_HTML.gif)
A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies | SpringerLink
![Noninvasive Evaluation of CD20 Expression Using 64Cu-Labeled F(ab′)2 Fragments of Obinutuzumab in Lymphoma | Journal of Nuclear Medicine Noninvasive Evaluation of CD20 Expression Using 64Cu-Labeled F(ab′)2 Fragments of Obinutuzumab in Lymphoma | Journal of Nuclear Medicine](https://jnm.snmjournals.org/content/jnumed/62/3/372/F1.large.jpg)
Noninvasive Evaluation of CD20 Expression Using 64Cu-Labeled F(ab′)2 Fragments of Obinutuzumab in Lymphoma | Journal of Nuclear Medicine
![Lymphoma: Radioimmunotherapy Using Iodine-131 Labeled Murine Anti-CD20 Antibodies (131I-Tositumomab and Tositumomab, “Bexxar”) | Radiology Key Lymphoma: Radioimmunotherapy Using Iodine-131 Labeled Murine Anti-CD20 Antibodies (131I-Tositumomab and Tositumomab, “Bexxar”) | Radiology Key](https://radiologykey.com/wp-content/uploads/2016/09/A139041_1_En_943_Fig2_HTML.gif)
Lymphoma: Radioimmunotherapy Using Iodine-131 Labeled Murine Anti-CD20 Antibodies (131I-Tositumomab and Tositumomab, “Bexxar”) | Radiology Key
![Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises | Immunotherapy Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises | Immunotherapy](https://www.futuremedicine.com/cms/10.2217/imt-2015-0015/asset/images/medium/figure2.gif)
Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises | Immunotherapy
![Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy](https://www.spandidos-publications.com/article_images/ijo/47/5/IJO-47-05-1735-g07.jpg)
Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy
![Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease | PNAS Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease | PNAS](https://www.pnas.org/cms/10.1073/pnas.1810470115/asset/45698723-b8ca-4f52-a9d1-bfc263c1e487/assets/graphic/pnas.1810470115fig06.jpeg)
Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease | PNAS
![Potential anti-CD20 mAb effector mechanisms. (A) Fc-Fc ␥ R–dependent... | Download Scientific Diagram Potential anti-CD20 mAb effector mechanisms. (A) Fc-Fc ␥ R–dependent... | Download Scientific Diagram](https://www.researchgate.net/publication/49731828/figure/fig1/AS:297465887641602@1447932802136/Potential-anti-CD20-mAb-effector-mechanisms-A-Fc-Fc-R-dependent-mechanisms-The-Fc.png)